Non-metastatic Breast Cancer Clinical Trial
Official title:
RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02650193 -
A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.
|
Phase 2 | |
| Active, not recruiting |
NCT02530177 -
Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer
|
||
| Recruiting |
NCT06400849 -
Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy
|
N/A |